OraSure Technologies, Inc. (OSUR)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$3.48-2.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · OSUR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.4% |
| Our one-year growth estimate | diamond | 13.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 91.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
OSUR — earnings miss
Dated 2026-08-05
and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiali…
Why it matters: Changing the Board can help management. It can also get shareholders more involved.
Supportive ifShareholders agreed to the Board changes at the 2026 Annual Meeting.
Worry ifShareholders did not agree to the Board changes proposal.
Why it matters: Revenue growth in the diagnostics industry is a key priority for OraSure. It shows how well the company is doing in a competitive market.
Supportive ifQuarterly revenue growth in diagnostics exceeds 5% year over year.
Worry ifQuarterly revenue growth in diagnostics falls below 0% year over year.
Why it matters: This report will show if revenue growth in diagnostics is improving. Investors will focus on any signs of recovery.
Watch forQ2 revenue growth exceeds 5% year over year, indicating a positive trend.
Also watch forQ2 revenue growth is below 0%. This shows ongoing problems in the diagnostics market.
Why it matters: News about share buybacks can show management's trust in the company's worth and spending plans.
Supportive ifNews of more share buybacks over the current $40 million limit.
Worry ifNo further share repurchases announced or a pause in the program.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$167 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $389 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,757 loss on $10,000 · 37.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Approval would support the company's innovation plan. It could help future revenue growth.
Supportive ifFDA approval of the InteliQuick CT/NG test submission.
Worry ifThere may be more delays or a rejection of the InteliQuick CT/NG test.
Why it matters: If revenues fall below this range, it shows ongoing revenue problems. This would hurt growth.
Worry ifIn Q3 2026, total revenues were less than $29.5 million.
Less concerning ifIn Q3 2026, total revenues were more than $32.5 million.
Why it matters: A drop below this level may show problems with cost control and efficiency.
Worry ifQ3 2026 gross margin reported below 42%.
Less concerning ifQ3 2026 gross margin reported above 43.5%.
Why it matters: More share buybacks could show management's trust in the company's value and finances.
Supportive ifTotal share buybacks were over $10 million for 2026.
Worry ifShare buybacks were under $5 million for 2026.